Details of most recent positions
Independent Expert Witness - Various Cases - May 09 to present
Biota Holdings – Expert Consultant – Feb 04 to Aug 08
| Expert consultant to lawyers engaged in commercial litigation
| Explained complex scientific issues to the legal team
| Assisted in the preparation of questions for expert witnesses
| Prepared technical reports, chronologies and literature reviews for the case
Cryptopharma – Chairman – Dec 03 to Apr 08
| Chaired Board meetings as an independent, non-executive Director
| Participated in Scientific Advisory Board meetings during the initial years of the Company
Boron Molecular - CEO & Managing Director - Mar 02 to May 03
| Overall responsibility for the management of the Company
| Stabilized the business & recruited management team
| Raised $1.9M through a private placement
| Wrote new business plan for redirection of corporate strategy
| Prepared prospectus for a public offering
| Grew revenues in 1st three quarters of 2002/3 by >100% compared with same period in 2001/2
| Attained near breakeven
| Established systems and quality control procedures
Biota Holdings – Director R&D/General Manager - Sep 93 to Feb 02
| Responsible for all research and development activities of the Company
| Initiated and completed development of the flu diagnostic, FLU OIA®, for international marketing
| Built R&D team as inaugural R&D Director
| Established laboratory facilities
| Managed R&D relationship with GSK on Relenza®
| Diversified Biota’s R&D portfolio
Parke-Davis (Ann Arbor, MI, USA) – Director, Clinical Pharmacology – Sep 90 to Sep 93
| Managed transition of new pharmaceuticals for CNS diseases from pre-clinical to Phase I and Phase IIA clinical studies
| Managed staff involved in Phase I and IIA CNS studies
| Prepared clinical pharmacology reports for IND and NDA applications
| Reviewed pre-clinical data for suitability for IND applications and Phase I studies in CNS
| Attended all research and team meetings in the CNS preclinical and clinical area
